

Recto

145 mm

11.5

297 mm

PHARMA CODE REF: IS-262

72 mm

9

9

11.5



Otrivin

Patient Information Leaflet (PIL)
Otrivin
 Xylometazoline Hydrochloride

Otrivin 0.1% (each ml contains 1 mg Xylometazoline Hydrochloride)
 Otrivin 0.1% Metered-Dose Nasal Spray
 Otrivin 0.1% Nasal Drops

Otrivin 0.05% (each ml contains 0.5 mg Xylometazoline Hydrochloride)
 Otrivin 0.05% Metered-Dose Nasal Spray
 Otrivin 0.05% Nasal Drops

Otrivin Nasal Drops and Metered-Dose Nasal Sprays are for Nasal administration ONLY

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
 Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.

• Keep this leaflet. You may need to read it again.
 • Ask your pharmacist if you need more information or advice.
 • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
 • You must talk to a doctor if you do not feel better or if you feel worse.

In this leaflet:
 1. What Otrivin is and what it is used for?
 2. What you need to know before you use Otrivin?
 3. How to use Otrivin?
 4. Possible side effects
 5. How to store Otrivin
 6. Contents of the pack and other information

1. What Otrivin is and what it is used for?
 Otrivin is used for various types of colds. It is designed to be applied in the nostrils, where it exerts a vasoconstricting effect thereby decongesting the mucosa of the nose and the throat. This effect allows patients with colds to breathe more easily through the nose. The action of Otrivin is felt within a few minutes and lasts for several hours. Otrivin contains ingredients which help prevent the nasal mucosa drying out. Otrivin is used for Otrivin Medo as an adjunct for decongestion in the nasopharyngeal area. Also used for easing of rhinoscopy.

2. What you need to know before you use Otrivin?
a. Do not use Otrivin if:
 • You are allergic to xylometazoline or any other ingredients of this medicine.
 • You have undergone recent brain surgery (brain surgery where the operation was carried out through the nose or mouth).
 • You have narrow angle glaucoma (increased pressure in eyes).
 • You have chronic nasal inflammation with very dry nasal passages (rhinitis sicca or atrophic rhinitis).
 • Tell your doctor or pharmacist if any of the above apply because Otrivin is not suitable for you in these circumstances.

b. Warnings and precautions
 Talk to your doctor or pharmacist before using Otrivin if:
 • You have high blood pressure.
 • You suffer from a heart disease.
 • You have an overactive thyroid gland (hyperthyroidism).
 • You suffer from diabetes.
 • You have an enlarged prostate gland (prostatic hypertrophy).
 • You have a benign tumour of the adrenal gland that produces high amounts of adrenaline and noradrenaline (pheochromocytoma).
 • You are being treated with some antidepressants known as monoamine oxidase inhibitors (MAOIs) or if you have used them within the previous 2 weeks.
 If any of the above apply, do not use Otrivin before talking to your doctor or pharmacist.
 • Like other products for the relief of blocked nose, Otrivin may give rise to sleep disturbances, dizziness, tremor in very sensitive patients. Consult your doctor if such signs prove troublesome.
 • Like other nasal decongestants, Otrivin should not be used for more than 7 consecutive days. If symptoms persist, consult your doctor. Prolonged or excessive use may cause stuffiness in the nose to return or worsen.
 • Otrivin is not intended for use in the eyes or mouth.
 • Do not exceed the recommended dosage, especially in children and in the elderly.
 • Otrivin 0.1% metered-dose spray and Otrivin 0.1% nasal drops should not be used for children below 12 years of age.
 • Otrivin 0.05% (nasal drops and metered-dose spray) should not be used in children under 1 year of age. For children aged from 1 to 2 years, use only according to the doctor's prescription. Children aged from 2 to 11 years, use only under adult supervision.
 • This product contains Sodium to be taken into consideration by patients on controlled Sodium diet. Contact your doctor if you have an intolerance to some sugars.

c. Taking Other medicines with Otrivin:
 Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, you should not use Otrivin if you are taking:
 • Certain medicines used for treatment of depression. These medicines are:
 • Monoamine oxidase inhibitors (MAOIs): do NOT use Otrivin if you are taking or have been taking MAOIs within the last 14 days.
 • Tricyclic and tetracyclic antidepressants.
 • Potentially hypertensive medicines or medicines for Parkinson's disease (levodopa).
 If you use any of the above medicines, consult a doctor before using Otrivin.





d. Pregnancy and breast-feeding
 Otrivin should not be used during pregnancy.
 • The use of Otrivin while breast-feeding should only take place on the instructions of a doctor.
 • Fertility: There are no relevant data on the effect of Otrivin on fertility, and controlled studies in animals are not available. Since systemic exposure to xylometazoline is very low, effects on fertility are highly unlikely.
 • Ask your doctor or pharmacist for advice before taking any medicine.

e. Driving and using machines
 • If used within the recommended dosing, there is no or negligible influence on the ability to drive and use machines.
 • If used over a longer term or at higher doses, the potential for systemic activity with cardiovascular effects cannot be excluded.

3. How to use Otrivin?
 • Otrivin Nasal Drops and Metered-Dose Nasal Sprays are for Nasal administration ONLY.
 • Do not get Otrivin in the mouth or eyes.
 • Do not exceed the recommended dose, especially in children and the elderly.
 • It is recommended to make the last application shortly before going to bed.
 • Otrivin should not be used for longer than 1 week since prolonged use can lead to damage to mucosa (rhinitis medicamentosa).
 • Always use Otrivin exactly as recommended below. You should check with your doctor or pharmacist if you are not sure.

Product	Dose	Age
Otrivin 0.05% Nasal Drops	1-2 drops of 0.05% solution, 1-2 times a day in each nostril are usually sufficient. Do not exceed 3 applications per day.	Children Under 1 year of age should NOT use the product. Children between 1-2 years old: only use as prescribed by a doctor.
Otrivin 0.05% Metered-Dose Nasal Spray	1 spray pull of the 0.05% metered-dose spray in each nostril are usually sufficient. Do not exceed 3 applications per day.	Children between 2-11 years old: only use under adult supervision.
Otrivin 0.1% Nasal Drops	2-3 drops of 0.1% solution, in each nostril. Repeat as needed, however do not exceed 3-4 applications per day.	Not to be used for Children under 12 years of age
Otrivin 0.1% Metered-Dose Nasal Spray	1 spray pull of 0.1% metered-dose nasal spray in each nostril. Repeat as needed, however do not exceed 3 applications per day.	Only for adults and adolescents from 12 years and over

6200000211382

TECHNICAL INFORMATION		
6200000123456	SITE COMPONENT NUMBER 123456 : DUMMY for positioning only Background: No color Use the 14-digit site component number	
 	PHARMACODE AREA TEXT & GRAPHICS FREE STARTING POINT ON THE LEFT BAR HEIGHT : 7.0 mm CODE LENGTH : VARIABLE	
	TEXT AND GRAPHIC FREE AREA Blank or Technical Area	
	COPY AREA Text and Graphic Area	
CUT		
Legacy number = P07		
STUDIO REFERENCE No.	N/A	
SUPPLIER REFERENCE No.	N/A	
DRAWING OWNER (SITE)	NYON	
LEAFLET 145 X 297 MM		
DRAWING No.	AWDRG-1016	V1
COPYRIGHT AND DESIGN RIGHT IS THE PROPERTY OF HALEON		
SCALE: 1:1 ALL DIMS. IN MILLIMETRES	GENERAL DRAWING TOLERANCE UNLESS STATED OTHERWISE N/A	

V1		Artwork Information Panel		HALEON	
05 - APR - 2024					
Non Production Artwork		Production Artwork		X	
Total Number of Colours including Varnish & Foils: 1					
1. Black	2.	3.	4.	5.	6.
7.	8.	9.	10.	11.	12.
Total Special Finishes: 0					
Component No: AWP No:		6200000211382 7651575			
Manufacturing Site:		Nyon			
Approving Market:		Bahrain-BHR, Jordan-JOR, Kuwait-KWT, Lebanon-LBN, Oman-OMN, Qatar-QAT, United Arab Emirates-ARE			
Technical Drawing No:		(P07) AWDRG-1016 v1			
Material Spec No:		P07			
Body Text Size:		4.8pt			
Smallest Text Size:		4.2pt			
Electronic Verification Code:		262			
Printer and User notes:					

